3 November, 2026 | The Waldorf Astoria Hotel, Versailles, France
Operationalizing ICH GCP E6(R3)
Agenda
Discover how sponsors maintain clinical oversight in light of ICH E6(R3) and risk-based quality management (RBQM). Learn sponsor strategies for operating model change, including vendor management, internal resourcing, and technology adoption.
Pinar Bérénice Bénet
Senior Director Clinical Strategy
Veeva
With the release of ICH GCP E6(R3), sponsors are re-evaluating how their operating models support data management and monitoring oversight. This interactive opening session uses a live participant survey to explore how fully outsourced, hybrid, and sponsor-led approaches affect CRO delegation, risk detection, and sponsor accountability. Real-time results will benchmark current industry practices and frame the discussions ahead.
Francesca Fasesin
Engagement Manager, Clinical Data
R&D Business Consulting, Veeva
Ibrahim Kamstrup-Akkaoui
Senior Director, R&D Digital Transformation
Novo
As clinical development becomes increasingly outsourced, sponsors need to maintain visibility and oversight while keeping responsibilities with their CRO partners. In this session, Debiopharm will share how it uses Veeva CTMS to support its clinical operating model across FSO and FSP engagements.
Yulia Urfer
Head of Clinical Operations
Debiopharm
ICH GCP E6(R3) is raising expectations for how sponsors manage oversight of outsourced clinical trials. In this session, the Veeva Systems product team will share how Veeva CTMS is evolving to support oversight planning, decision-making, and issue management, with a deep dive into the upcoming 26R3 release and a look at the future of proactive, risk-based oversight.
Florent Lusardi
Principal Product Expert
Clinical Operations, Veeva
As ICH E6(R3) shifts clinical research toward risk-proportionate quality management, organizations must establish metrics that ensure reliable data and proactive sponsor oversight. In this interactive roundtable session, participants will debate data governance challenges and define actionable Key Risk Indicators (KRIs) and KPIs for trial quality and vendor oversight. Attendees will leave with practical, peer-tested metrics to strengthen their organization’s RBQM and data governance strategies.
Pinar Bérénice Bénet
Senior Director Clinical Strategy
Veeva
With ICH E6(R3) placing greater emphasis on proactive quality management and sponsor accountability, organisations must demonstrate effective oversight regardless of their operating model. For companies that rely on full-service CRO partnerships, this requires more than monitoring vendor performance. It demands clear governance, robust risk management processes, and strong internal ownership of quality decisions.
In this session, Emma Forrest shares how Recordati is implementing its in-house RBQM strategy while operating under a fully outsourced model. She will outline Recordati’s approach to building internal risk evaluation capabilities, managing system and process change with CROs, and aligning with R3 standards alongside full-service partners.
In this session, Emma Forrest shares how Recordati is implementing its in-house RBQM strategy while operating under a fully outsourced model. She will outline Recordati’s approach to building internal risk evaluation capabilities, managing system and process change with CROs, and aligning with R3 standards alongside full-service partners.
Emma Forrest
VP of Clinical Operations
Recordati
To demonstrate how to meet ICH E6(R3) mandates for stronger sponsor oversight and centralized data review, the Veeva product team will showcase the roadmap for Veeva DQS and Veeva CTMS. Find out how connecting CTMS and DQS operationalizes regulatory expectations, enables early risk and anomaly detection using Critical-to-Quality (CtQ) signals, and streamlines workflows across sponsor and vendor teams.
Drew Garty
Chief Technology Officer
Clinical Data, Veeva
Tom Dekker
VP Product Management
Clinical Operations, Veeva
Learn how Syneos Health and Excelya optimize sponsor-CRO collaboration through governance, flexible resourcing, and system integration. Discover how they maintain quality, compliance, and data integrity while managing stakeholder expectations and operational risk.
Pierrick Bourgouin
Chief Operating Officer
Excelya